There’s a new cancer drug on the market which targets genetic mutation instead of cancer type. The FDA has approved Vitrakvi which costs 393-thousand dollars a year, wholesale. The drug is the first of its kind to treat cancers based solely on a specific genetic mutation. It’s designed to fight cancers that arise anywhere in the body which carry a certain genetic characteristic. Typically, cancer therapy targets the part of the body where the cancer arises. In a statement, FDA Commissioner Dr. Scott Gottlieb said this “approval marks another step in an important shift toward treating cancers based on their tumor genetics rather than their site of origin in the body.”
###
Wafa Shahid/kds
Copyright © 2018
TTWN Media Networks LLC
